At Adamas Pharmaceuticals, Inc., our purpose and vision are clear: deliver innovative medicines that make everyday life significantly better for patients, caregivers and society. We are an emerging, fully-integrated company focused on neurological diseases with a proven track record of turning this purpose into reality by combining expertise in development and commercialization with a passion for improving lives. 

In 2018, Adamas successfully launched GOCOVRI® (amantadine) extended-release capsules, the first and only FDA-approved medicine for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. GOCOVRI is also the only medicine clinically proven to reduce both dyskinesia and OFF.

News and Events


Stock Information